Author: admin

Seven clinical trials testing the use of potential breakthrough combination therapies to treat debilitating mental illnesses will receive a total of almost $15 million from the Morrison Government’s Medical Research Future Fund (MRFF).
It is estimated four million Australians experience a mental health disorder ever year, and almost half of all Australians will be affected at some point in their lifetime. Depression, anxiety, and substance use disorders are the most common mental illnesses affecting Australians. Not all patients achieve good results from standard treatments, and few new medications have become available in recent years.
However, there is growing evidence that substances such as psilocybin, and 3,4-Methylenedioxymethamphetamine (MDMA), dimethyltryptamine (DMT), and cannabidiol (CBD) when used in a controlled environment and supported by psychological/ psychiatric care, may help treat mental illness that has not responded to other treatments.
The seven projects awarded funding under the Government’s Innovative Therapies for Mental Illness Grant will accelerate global efforts to find new treatments for mental illness by supporting Australian-led research into the safety and efficacy of these drugs compared to standard therapies when used in controlled conditions and accompanied by psychotherapy.
The trials have the potential to provide breakthrough treatment for people suffering from persistent mental illness including major depression with alcohol use, anorexia nervosa, post-traumatic stress disorder (PTSD) and anxiety disorders.
The largest of the grants, more than $3.8 million, will go to a research team at the University of Melbourne for a trial of MDMA-assisted psychotherapy for treatment resistant social anxiety in young adults with autism spectrum disorder. Social anxiety is common in young adults with autism and adds to their disability and distress. Current treatments are often ineffective.
Other trials will use psilocybin for anorexia nervosa, depression and alcohol use; MDMA for alcoholism and post-traumatic stress disorder; CBD for anxiety disorders in youth; and DMT for major depression and alcohol use.
All the trials are subject to regulatory approvals, including additional approval requirements from states and territories for the use of these drugs.
Minister for Health and Aged Care, Greg Hunt, said the Government’s MRFF is helping ensure that Australia’s medical research sector remains at the forefront of global innovation.
“It is vital that we continue to support the search for new and better treatments for mental illness. This funding will boost local research into potentially life-saving therapies and offers hope all those suffering from mental illness,” Minister Hunt said.
Assistant Minister to the Prime Minister for Mental Health and Suicide Prevention, David Coleman, said mental health and suicide prevention is one of the Government’s highest priorities.
“The prevalence and impact of mental illness is devastating for individuals, families and communities. This research is about ensuring that we explore every avenue of potential treatment for Australians diagnosed with a mental illness,” Assistant Minister Coleman said.
The Government’s Medical Research Future Fund is a $20 billion endowment fund, providing sustainable support for Australia’s best and brightest researchers. Further information about the Medical Research Future Fund is available at www.health.gov.au/mrff

National Cabinet met today to discuss our response to COVID-19 and the Omicron variant, new approaches to test, trace isolate and quarantine including the use of rapid antigen tests (RATs) and the vaccine rollout and booster programme.
The Chief Medical Officer Professor Paul Kelly provided an update on the spread of the Omicron variant. Omicron case numbers continue to increase in Australia and globally. Omicron continues to show greater infectivity than the Delta variant, but with less severity.
Since the beginning of the pandemic there have been 612,106 confirmed cases in Australia and, sadly, 2,289 people have died. More than 56 million tests have been undertaken, with 1,643,841 million tests reported in the past 7 days.
Globally there have been over 294.9 million cases and sadly over 5.4 million deaths, with 2.6 million new cases and 7,169 deaths reported in the last 24 hours. The COVID-19 pandemic continues to surge in many countries around the world.
National Cabinet received a detailed update on Australia’s COVID-19 vaccination program from Lieutenant General John Frewen, Coordinator General of Operation COVID Shield.
Australia’s COVID-19 vaccine roll out continues to expand. To date 43 million doses of COVID-19 vaccines have been administered in Australia, including 212,497 in the previous 24 hours.
In the previous 7 days, more than 754,500 vaccines have been administered in Australia. More than 94.5 per cent of the Australian population aged 16 years and over have now had a first dose of a COVID-19 vaccine, including 98.7 per cent of Australians aged 50 years of age and over and more than 99 per cent of Australians aged 70 years of age and over.
More than 91.6 per cent of Australians aged 16 years and over are now fully vaccinated including more than 96.8 per cent of Australians aged 50 years of age and over and more than 99 per cent of Australians aged 70 years of age and over.
Over 2.7 million booster doses have been administered. Australia has sufficient supplies of boosters, with nearly 18 million mRNA vaccines in stock in Australia. Yesterday, over 176,000 boosters were administered across Australia. Following the widening of eligibility for boosters on 4 January to those who had their second dose at least four months earlier, over 33.8 per cent of those eligible for boosters have had a booster and 28.6 per cent of Australians aged 70 years of age and over have had a booster in the last 8 weeks since the booster program commenced.
National Cabinet will meet again on Thursday 13 January 2022.
Rapid Antigen Tests
National Cabinet noted that COVID-19 tests are free and available at state testing clinics for people who have symptoms or are a close contact.
National Cabinet agreed that up to 10 Rapid Antigen Tests over three months (a maximum of 5 in a month) will be made available free through pharmacies to people holding the following cards:

• Pension Concession Card
• Commonwealth Seniors Health Care Card
• Department of Veterans’ Affairs Gold, White or Orange Card
• Health Care Card
• Low Income Health Card

These free tests will become available in the next two weeks. However, anyone with COVID-19 symptoms and close contacts should attend a state clinic for free testing and not go to a pharmacy to receive a free test. Costs for providing these tests will be shared 50:50 between the Commonwealth and the States and Territories consistent with COVID shared funding agreements.
National Cabinet noted the Commonwealth will provide 10 million RATs to states and territories (a combination of predominantly Point of Care Tests and self tests) to assist with testing and laboratory capacity. National Cabinet agreed to fund these in line with the existing National Partnership Agreement on the COVID-19 Response.
National Cabinet received a briefing from Joe Buffone, Director-General of Emergency Management Australia, on behalf of the National Coordination Mechanism (NCM). Supply chain issues continue to be one of the main disruptors of broad access to RATs. National Cabinet noted that the Commonwealth is working through the NCM to finalise anti-hoarding measures with the Pharmacy Guild of Australia and other major retailers that stock RATs to limit the number of RATs available for sale to each individual.
National Cabinet noted the Commonwealth will prohibit price gouging of and the non-commercial export of RATs, similar to actions taken earlier in the pandemic relating to essential goods such as masks, other PPE and hand sanitiser. As was the case previously, price gouging will be defined as supplying or offering to supply essential goods at a price that is more than 120% of the initial purchase price (a 20% markup) and penalties for not complying with this direction will range up to five years imprisonment or $66,000.
Changes to testing requirements
National Cabinet agreed changes to testing requirements for all states except for Western Australia including:

• Removing the requirement for truck drivers to have rolling seven days tests.
• Testing will not be required before patients present to hospital.
• Confirmation PCR test will not be required after a positive RAT. Individual states and territories will provide further information on how a positive RAT will be recorded. Anyone who tests positive is encouraged to contact their GP for support as required.
• Testing before interstate travel will no longer be required except for Queensland, Tasmania and Western Australia, with Queensland and Tasmania to review these requirements in the coming weeks. State testing clinics will not be able to be used for interstate travel purposes.
• A second post arrival test for international travelers will not be required except for Queensland, who will review this requirement when they reach 90 per cent double vaccination rate.

Workplace Health and Safety
National Cabinet noted the impact on business of current state workplace Health and Safety laws that could imply requiring employees to return a negative RAT test in order to present to work. National Cabinet agreed the Commonwealth Attorney General will convene a meeting of relevant ministers from all jurisdictions to consider workplace health and safety requirements with a view to removing any potential obligation to impose testing requirements in workplaces on employees
National Return to School Framework
National Cabinet tasked the First Secretaries Group (FSG) let by Mr Phil Gaetjens, Secretary of the Department of Prime Minister and Cabinet to develop a national framework to enable students to return to school on day one of term one, and for schools to stay open with consistent requirements across all jurisdictions to be in place prior to the first day of the first term of school. The FSG will report back to National Cabinet at the next meeting.

Two clinical trials which could save lives through new therapies to treat breast cancers that have low rates of survival have been funded, thanks to the Morrison Government.
Tragically, young women diagnosed with breast cancer have a higher rate of recurrence and death from the disease.
To combat this, researchers at the University of Melbourne have conducted a genomic analysis of breast cancer samples from women under 45 years of age. They have identified a new drug target that may improve the prognosis for these young women.
The Morrison Government is directing more than $4.9 million to the researchers to evaluate these new therapies in a clinical trial.
In addition, researchers at the University of New South Wales have turned their attention to treatment resistant triple-negative breast cancer, where new therapies are urgently needed to improve survival rates.
The researchers discovered that blocking what’s called an androgen receptor prevents and treats chemotherapy-resistant triple-negative breast cancer. Pre-clinical models have shown that, when combined with chemotherapy, overall survival rates are significantly improved.
The researchers will use almost $670,000 in Government funding to test this new therapy in a clinical trial.
The funding for both of these trials has been provided through the Medical Research Future Fund’s (MRFF) Rare Cancers, Rare Diseases and Unmet Need (RCRDUN) clinical trials initiative.
There are limited effective treatment options for many rare cancers and diseases, and the combined health burden is significant.
Through RCRDUN, the Government is increasing trial activity in Australia, supporting high quality research and encouraging novel and innovative treatments.
The two projects announced today are a small part of the 2021 RCRDUN grant program. A further 6 streams are being assessed and recipients will be announced in due course.
The $20 billion MRFF is a long-term investment supporting Australia’s best and brightest researchers. Further information about the MRFF is available at www.health.gov.au/mrff
MRFF 2021 Clinical Trials Activity – Rare Cancers, Rare Diseases and Unmet Need (RCRDUN) Grant Opportunity – Stream 2

Labor calls on the Morrison Government to make Rapid Antigen Tests free for Australians via Medicare.
We have been saying for some time that nobody should be denied a test because they can’t afford one.
We have considered the options and it is clear that this is the simplest, most efficient, fairest and most responsible way to fix the mess that Scott Morrison has made of testing at this critical juncture of the pandemic.
As always, we are prepared to work with the Government to determine the best way to provide free tests through the Medicare system.
It’s clear from Scott Morrison’s ridiculous proposal today that he has absolutely no appreciation of the skyrocketing cost of these tests or the consequences of his failure to order enough of them, quickly enough.
We can’t have people at their most vulnerable and contagious being ripped off, or going undiagnosed, or travelling around cities, suburbs and towns searching in vain for tests they can’t find or afford.
Price is one consideration, we also need the Prime Minister to fix the supply issues he is responsible for as well.
In recent days we have been carefully considering the most economically responsible course of action and it’s clear that the cost of tests are dwarfed by the costs of the Prime Minister’s failures to do his job, his undermining of Medicare, and the economic and health consequences of people not being able to test for the virus.
This can’t wait for a change of government.
Scott Morrison needs to act now. His inability to take responsibility has cost Australians too much already.